Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Methamphetamine is an addictive stimulant drug that strongly activates certain parts of the brain. The purpose of this study is to determine the effectiveness of bupropion in combination with behavioral therapy for the treatment of methamphetamine addiction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Collaborator: University of California, Los Angeles
• Treatments: Bupropion; Methamphetamine

Criteria

Inclusion Criteria:

• Meets DSM-IV criteria for methamphetamine dependence

• Females must use an effective method of contraception

Exclusion Criteria:

• History of or current medical condition that might interfere with safe participation, such as active tuberculosis, unstable heart or liver disease, unstable diabetes, symptomatic AIDS (non-symptomatic HIV infection is not an exclusion), or greater than 8 times the upper limit of normal in liver screening function tests (SGOT or SGPT)

• Current neurological disorder (e.g., organic brain disease, dementia)

• Major psychiatric disorder unrelated to substance abuse, such as schizophrenia or bipolar disorder (assessed by the SCID and a medical history)

• Suicide attempt within the month prior to enrollment and/or currently suicidal (assessed by the SCID and the BDI II)

• Currently on prescription medication that might interact with the study drug

• Currently dependent on cocaine, opiates, alcohol, or benzodiazepines, as defined by DSM-IV-TR criteria

• History of alcohol dependence within past three years

• History of seizure disorders

• History of anorexia or bulimia

• Current hypertension uncontrolled by medication

• History of sensitivity to bupropion

• Pregnant or breastfeeding